

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Breast cancer; prostate cancer	Globohexaosylceramide (globo-H); ganglioside GM2 (GM2); Thomsen-Friedenreich antigen (TF); Tn antigen (Tn); sialosyl-Tn antigen (sTn)	<p><i>In vitro</i> studies suggest that a pentavalent antigen conjugate could be part of a cancer vaccine. The vaccine was produced by conjugating five breast and prostate cancer-associated carbohydrate antigens—globo-H, GM2, TF, Tn and sTn—to a carrier protein. In serum samples from mice vaccinated with the construct, IgM and IgG antibodies against all five antigens were detected and the antibodies were reactive to a breast cancer cell line. Next steps include testing the vaccine construct in animal models of breast or prostate cancer.</p> <p>At least 21 companies have vaccines for breast and prostate cancer in clinical and preclinical testing.</p> <p><b>SciBX 2(26); doi:10.1038/scibx.2009.1035</b> Published online July 9, 2009</p>	Patent and licensing status unavailable	<p>Zhu, J. <i>et al. J. Am. Chem. Soc.</i>; published online June 11, 2009; doi:10.1021/ja901415s</p> <p><b>Contact:</b> Samuel J. Danishefsky, Sloan-Kettering Institute for Cancer Research, New York, N.Y. e-mail: <a href="mailto:s-danishefsky@ski.mskcc.org">s-danishefsky@ski.mskcc.org</a></p>